ANZCTR search results

This is an open-label, outpatient, multiple ascending dose study of AB-2004 in approximately 35 adolescent subjects diagnosed with ASD accompanied by gastrointestinal symptoms. The primary outcome is to assess the safety and tolerability of AB-2004 administered daily over a period of 8 weeks as assessed by the frequency and severity of adverse events and laboratory abnormalities. Secondary outcomes include assessments of the effects of AB-2004 on intestinal permeability, systemic levels of host and microbially derived metabolites, biomarkers of systemic inflammation, the fecal microbiome profile, gastrointestinal signs and symptoms, core behaviors and affect (particularly anxiety and irritability) and the measures of brain connectivity and white matter integrity.

The purpose of this study is to assessment the safety and tolerability of a new medication called FPT155. Who is it for? You may be eligible for this study if you are aged 18 or older and have a solid tumour. Study details All participants will be treated with a different amount of FPT155. This medication is administered through a needle in the arm once every 21 days for every 3 weeks .As part of this study, all participants will have a number blood tests, Hematology, Clinical chemistry, Coagulation, Urinalysis. It is hoped this research will demonstrate the safety and tolerability of this new medication and provide important does-related information for future studies.

There are currently no objective ways to diagnose migraine and there is no way to determine what underpins the origins of migraine in each individual. This leaves doctors and migraine sufferers without the key information that would allow for optimal treatment selection and specific diagnosis. What is needed is a simple test that can diagnose migraine patients from people without migraine and can guide treatment selection. This study will therefore explore whether some new technologies may be useful as a blood test(s) to diagnose migraine.

BIOMONITOR III First In Man Study aims to collect first implantation experience with a new generation of implantable cardiac monitors. BIOMONITOR III is a miniaturised version of its predecessor BIOMONITOR II which has sought to address the issue of increasing patient comfort with a smaller device, but still having all of the same diagnostic capability as BIOMONITOR II. The objective thus is to examine the ease of implant of the device by physicians, and to assess its full diagnostic capacity on patients.

People with interstitial lung disease often have poor quality of life because of distressing breathlessness and reduced exercise tolerance. Their survival is often poor and there are limited medical treatments available. There is no proven treatment for relieving symptoms in patients with these conditions. Handheld fans have been shown to be a useful intervention for breathlessness in patients with other lung conditions and cancers. This study aims to explore the use of a handheld fan, a simple and easily portable device, for symptom management in people with interstitial lung disease.

This is a multisite cluster randomized clinical trial of 300 patients across six clinical units in three tertiary acute hospitals to evaluate the clinical effectiveness of a pressure injury clinical judgement risk-screening and care planning tool in reducing pressure injuries. Standard care involves using the Waterlow pressure injury risk screening tool to determine a patient’s level of risk to develop a pressure injury. The intervention involves removing the Waterlow tool and using the pressure injury clinical judgement risk-screening and care planning tool. Our hypothesis is patients who receive the intervention have a lower incidence of HAPI compared to those patients who receive standard of care. The planned duration of this study is 12 months.

The most extensively investigated and characterised biomarker for in vivo imaging of neuroinflammation is the 18-kDa translocator protein (TSPO). Upregulation of TSPO expression, as visualised and quantified in vivo, has been associated with inflammation in common CNS disorders such as stroke, multiple sclerosis and Alzheimer’s disease. This study proposes to investigate whether PET imaging of TSPO radioligand [18F]GE-180 will serve as a robust diagnostic tool to predict neurlogical outcomes following spinal cord injury.

This trial is designed to assess the validity, reliability and responsiveness of an activity monitor, free walking app, ODI walk item, PFS and self-paced walking test

The purpose of this study is to determine if an extended use of a chemotherapy medication (temozolomide) after radiation improves survival outcome in patients with newly diagnosed brain cancer (also called a glioblastoma). Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with a glioblastoma. Study details Participants will take part in one of two treatment options: - In treatment 1, participants will continue with their usual care. - In treatment 2, participants will receive an additional six cycles of chemotherapy for 5 days, with each cycle lasting 28 days. The treatment that participants receive will be decided randomly. Participants enrolled into treatment option 2 will undergo routine blood tests prior to the administration of chemotherapy as per their standard care It is hoped that this research will determine if temozolomide is effective in increasing the overall survival rates, as well as the duration of survival of participants with glioblastoma.

The purpose of this study is to test the feasibility and effectiveness of conducting a nutrition intervention with patients experiencing chronic pain who attend Hunter Integrated Pain Service. Hypothesis: Participants who receive the personalized dietary advice and high anthocyanin concentration fruit juice will have a greater reduction in pain scores compared to those randomized to the waitlist control plus placebo fruit juice group.